Aclaris Therapeutics Call to Discuss Zunsemetinib Phase 2b Rheumatoid Arthritis Trial Results | Aclaris Therapeutics, Inc.

View all events »

Aclaris Therapeutics Call to Discuss Zunsemetinib Phase 2b Rheumatoid Arthritis Trial Results

Nov 13, 2023
8:00 AM EST

Click here for webcast

Supporting Materials

Aclaris Therapeutics Presents ATI-450 Phase 2b Rheumatoid Arthritis Data 815.8 KB